SLC35C2

Across TCGA pan-cancer cohorts, SLC35C2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of SLC35C2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SLC35C2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC35C2 is over-expressed in tumor.

HNSC, KIRC, and COAD are the cancer types where SLC35C2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC35C2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.717	<.001	12	view →
KIRC	Female	All	+0.526	<.001	12	view →
COAD	Male	III,IV	+1.125	<.001	11	view →
LIHC	Female	II,III,IV	+1.079	<.001	9	view →
KIRP	Male	II,III,IV	+0.908	<.001	9	view →
STAD	Male	II,III,IV	+1.116	<.001	8	view →
THCA	Female	All	+0.276	<.001	7	view →
BLCA	All	All	+0.644	<.001	6	view →
BRCA	All	II,III,IV	+0.342	<.001	6	view →
CHOL	Female	All	+1.766	<.001	5	view →
LUSC	All	All	+0.463	<.001	5	view →
LUAD	Female	All	+0.193	.011	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

SLC35C2–HNSC

Open the HNSC breakdown →